Martin Shkreli

martin@martinshkreli.com

|PFE.xlsx

|

Failures Master Pipeline Approved Products Management Main Model Comirnaty Ibrance Enbrel Paxlovid Eliquis Prevnar Inlyta Xeljanz Chantix Chantix Model Lorbrena Xalkori Myfembree etrasimod elranatamab giroctocogene PF-06425090 VLA15 Sutent Diflucan Cardura Vfend Zyvox Selzentry PF868554 Aricept Zithromax fordadistrogene Genotropin Accupril Fablyn tanezumab Acquisitions IP

	A	B	C
1	Main
2		Brand	PF-06425090
3		Generic
4		Clinical Trials
5			Phase III "CLOVER"
6			did not meet PE preventing CDI

Martin Shkreli